Lunai Bioworks (NASDAQ:RENB) Stock Price Up 21.7% – Here’s Why

Shares of Lunai Bioworks Inc. (NASDAQ:RENB) traded up 21.7% during trading on Wednesday . The stock traded as high as $1.43 and last traded at $1.54. 880,400 shares traded hands during trading, a decline of 77% from the average session volume of 3,746,845 shares. The stock had previously closed at $1.27.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lunai Bioworks in a research report on Saturday, September 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Lunai Bioworks Stock Performance

The company has a 50 day moving average price of $1.89 and a 200 day moving average price of $2.78. The company has a market capitalization of $250.24 million, a price-to-earnings ratio of -2.00 and a beta of 0.54.

Institutional Trading of Lunai Bioworks

Several hedge funds have recently bought and sold shares of the business. Nuveen LLC acquired a new position in shares of Lunai Bioworks during the first quarter valued at about $82,000. Jane Street Group LLC acquired a new position in Lunai Bioworks during the 2nd quarter valued at about $258,000. Marshall Wace LLP acquired a new position in Lunai Bioworks during the 2nd quarter valued at about $90,000. Finally, Qube Research & Technologies Ltd acquired a new position in Lunai Bioworks during the 2nd quarter valued at about $66,000. Institutional investors and hedge funds own 71.41% of the company’s stock.

About Lunai Bioworks

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.